Back to top

biotechs: Archive

Zacks Equity Research

Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4

Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

ACETNegative Net Change PBYINegative Net Change ADMAPositive Net Change RCKTPositive Net Change

Zacks Equity Research

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.

BMYNegative Net Change AMGNNegative Net Change SRPTPositive Net Change CTMXPositive Net Change

Zacks Equity Research

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

SRPTPositive Net Change CGENPositive Net Change PBYINegative Net Change CGEMPositive Net Change

Zacks Equity Research

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.

ACETNegative Net Change PBYINegative Net Change FATEPositive Net Change ADMAPositive Net Change

Zacks Equity Research

Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?

When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.

CLDXPositive Net Change ESPRPositive Net Change DERMPositive Net Change APLSNegative Net Change

Zacks Equity Research

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

AZNPositive Net Change MRKPositive Net Change SRPTPositive Net Change FUSNNegative Net Change

Zacks Equity Research

Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?

On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.

SRPTPositive Net Change CGENPositive Net Change ARQTPositive Net Change DNAPositive Net Change

Zacks Equity Research

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.

SRPTPositive Net Change CGENPositive Net Change ETONPositive Net Change ARQTPositive Net Change

Nalak Das

5 Stocks to Buy That Are Poised to Beat on Earnings This Week

We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.

CEGPositive Net Change IPARPositive Net Change HEINegative Net Change APLSNegative Net Change PCVXPositive Net Change

Zacks Equity Research

Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.

CLDXPositive Net Change ESPRPositive Net Change APLSNegative Net Change VTRSNegative Net Change

Zacks Equity Research

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

PBYINegative Net Change ADMAPositive Net Change EDITPositive Net Change BHCPositive Net Change

Zacks Equity Research

BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales

BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.

SNYPositive Net Change BMRNPositive Net Change ACETNegative Net Change PBYINegative Net Change

Zacks Equity Research

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.

REGNPositive Net Change PBYINegative Net Change VNDAPositive Net Change NTLAPositive Net Change

Zacks Equity Research

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

BMYNegative Net Change PBYINegative Net Change VNDAPositive Net Change KRTXNegative Net Change

Zacks Equity Research

Why Apellis (APLS) Might Surprise This Earnings Season

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

APLSNegative Net Change

Zacks Equity Research

Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

ACETNegative Net Change PBYINegative Net Change ITCIPositive Net Change ADMAPositive Net Change

Zacks Equity Research

Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View

Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

MRKPositive Net Change MRNAPositive Net Change ACETNegative Net Change PBYINegative Net Change

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

REGNPositive Net Change MRNAPositive Net Change SRPTPositive Net Change IOVAPositive Net Change RAPTNegative Net Change

Zacks Equity Research

Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y

Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.

RGENPositive Net Change PBYINegative Net Change VNDAPositive Net Change

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

VRTXNegative Net Change PBYINegative Net Change ADMAPositive Net Change CRSPPositive Net Change

Nalak Das

5 Stocks Likely to Gain on Q4 Earnings Today After Market Close

We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are: BKNG, AMH, FND, BMRN, PBA.

BMRNPositive Net Change PBAPositive Net Change AMHPositive Net Change FNDPositive Net Change BKNGNegative Net Change

Zacks Equity Research

Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag

Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.

RHHBYPositive Net Change JNJPositive Net Change HALOPositive Net Change EXASNegative Net Change

Zacks Equity Research

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

RHHBYPositive Net Change SRPTPositive Net Change ARQTPositive Net Change CGEMPositive Net Change

Zacks Equity Research

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.

JAZZNegative Net Change PBYINegative Net Change EXASNegative Net Change AXSMPositive Net Change

Zacks Equity Research

Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.

MRNAPositive Net Change SRPTPositive Net Change AMRNPositive Net Change AQSTPositive Net Change